Doximity
DOCS
$24.80
-6.73%
Doximity, Inc. operates a leading digital platform for healthcare professionals, connecting physicians with colleagues, medical news, and tools for telehealth, scheduling, and administrative tasks, while offering marketing, hiring, and workflow solutions to pharmaceutical companies and health systems. As the largest professional medical network in the U.S., it holds a dominant niche position with over 80% of U.S. physicians as members, creating a powerful network effect. The current investor narrative centers on the company's AI-driven product enhancements, which management claims deliver superior performance and 10x unit economics, sparking renewed optimism after a sharp stock decline in May 2026 following disappointing earnings and a slowdown in revenue growth. The debate now revolves around whether AI can reignite growth and justify the stock's recovery from its lows.…
DOCS
Doximity
$24.80
Related headlines
Investment Opinion: Should I buy DOCS Today?
Based on the analysis, I rate Doximity as a Hold. The stock is trading at $20.66, with an analyst consensus rating of 'Buy' and an average target price of $24.61, implying a modest upside of about 19%. However, the wide range of targets (low $18, high $42) and the recent growth deceleration warrant caution. The thesis is that Doximity's dominant market position and exceptional profitability provide a floor, but the near-term growth slowdown limits upside until there is evidence of reacceleration.
Sign up to view all
DOCS 12-Month Price Forecast
The AI assessment is neutral with medium confidence. While Doximity's AI initiatives could provide a significant growth catalyst, the evidence so far is anecdotal and has not yet reversed the deceleration trend. The stock's low forward PE suggests that the market is already pricing in a pessimistic scenario, offering a favorable risk/reward if AI succeeds. However, the lack of concrete data on AI's impact on revenue and the persistent growth slowdown warrant caution. I would upgrade to bullish if the next earnings report shows revenue growth reaccelerating above 15% YoY or if management provides specific metrics on AI-driven customer wins. Conversely, I would downgrade to bearish if growth falls below 5% or if margins compress significantly.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Doximity's 12-month outlook, with a consensus price target around $29.11 and implied upside of +17.4% versus the current price.
Average Target
$29.11
0 analysts
Implied Upside
+17.4%
vs. current price
Analyst Count
—
covering this stock
Price Range
$18 - $47
Analyst target range
The target price range spans from a low of $18.00 to a high of $42.00, representing a wide spread of 133% between the low and high. The low target of $18 implies a 13% downside from the current price, reflecting concerns about continued revenue deceleration and competitive pressures. The high target of $42 suggests a 103% upside, likely assuming that AI-driven products accelerate growth and expand margins significantly. The wide range indicates high uncertainty about the company's future trajectory, with analysts divided on whether the recent growth slowdown is temporary or structural. The recent upgrade from JP Morgan and Canaccord Genuity suggests some analysts see value at current levels, but the overall sentiment remains cautious given the stock's recent volatility.
Bulls vs Bears: DOCS Investment Factors
Doximity presents a classic high-risk, high-reward investment case. On the bull side, its dominant market position, exceptional profitability, and AI-driven growth initiatives offer a compelling long-term story, supported by an attractive forward valuation. On the bear side, the sharp deceleration in revenue growth, deep stock downtrend, and wide analyst target range reflect significant near-term uncertainty and negative sentiment. Currently, the bear case appears stronger given the persistent growth slowdown and the stock's technical weakness, but the potential for AI to reaccelerate growth and the low forward PE provide a substantial upside if the company can execute. The single most important tension is whether the recent growth deceleration is a temporary blip or a structural shift, as this will determine whether the stock is a value trap or a turnaround opportunity.
Bullish
- Dominant market position: Doximity connects over 80% of U.S. physicians, creating a powerful network effect that is difficult for competitors to replicate. This entrenched user base provides a durable competitive moat and a strong foundation for monetization.
- Exceptional profitability metrics: The company boasts a gross margin of 89.1% and a net margin of 30.4%, reflecting a highly scalable subscription-based business model. Operating margin of 33.3% further underscores operational efficiency and pricing power.
- AI-driven growth catalysts: Recent news highlights that AI investments are delivering superior performance and 10x unit economics, signaling potential for accelerated growth and margin expansion. This has sparked renewed optimism and could reaccelerate revenue growth beyond the current 9.8% YoY.
- Attractive forward valuation: With a forward PE of 13.0x, the stock trades at a significant discount to its trailing PE of 22.2x, implying the market expects strong earnings growth. This valuation is compelling for a company with 30%+ net margins and a dominant niche.
Bearish
- Sharp revenue growth deceleration: Revenue growth slowed from 23% YoY in Q3 FY2025 to just 9.8% in Q3 FY2026, raising concerns about market saturation and competitive pressures. This deceleration has been a primary driver of the stock's 64.5% decline over the past year.
- Stock in a deep downtrend: The stock is trading at $20.66, near its 52-week low of $17.15 and 73% below its high of $76.51. The 1-year price change of -64.5% and negative relative strength versus the S&P 500 indicate persistent selling pressure and weak investor sentiment.
- High valuation uncertainty: The analyst target range is extremely wide, from $18 to $42, reflecting deep disagreement about the company's future. The low target implies 13% downside, while the high target suggests 103% upside, highlighting the high risk and uncertainty.
- Dependence on subscription revenue: Subscription revenue accounts for 94.8% of total revenue, making the company highly dependent on a single revenue stream. Any slowdown in subscription growth or customer churn would have an outsized impact on financial performance.
DOCS Technical Analysis
Doximity's stock is in a pronounced downtrend, with a 1-year price change of -64.5% and a 52-week range of $17.15 to $76.51. The current price of $20.66 sits near the bottom of this range, at approximately 6% above the 52-week low and 73% below the high, indicating that the stock is deeply depressed and trading near its lowest levels. This positioning suggests the market has priced in significant pessimism, but also leaves the stock vulnerable to further downside if fundamentals deteriorate, while offering potential upside if a turnaround materializes.
Beta
1.21
1.21x market volatility
Max Drawdown
-76.0%
Largest decline past year
52-Week Range
$17-$77
Price range past year
Annual Return
-61.0%
Cumulative gain past year
| Period | DOCS Return | S&P 500 |
|---|---|---|
| 1m | +11.4% | +2.9% |
| 3m | +30.7% | +5.0% |
| 6m | -0.9% | +13.9% |
| 1y | -61.0% | +20.4% |
| ytd | -42.7% | +13.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
DOCS Fundamental Analysis
Doximity's revenue growth has been decelerating, with the most recent quarter (Q3 FY2026, ended December 31, 2025) showing revenue of $185.1 million, up 9.8% year-over-year, compared to 23% growth in the prior year quarter. The sequential trend shows revenue rising from $138.3 million in Q4 FY2025 to $145.9 million in Q1 FY2026, $168.5 million in Q2, and $185.1 million in Q3, indicating a steady sequential acceleration, but the YoY growth rate has slowed from 23% to 9.8% over the same period. Subscription revenue of $175.4 million dominates, representing 94.8% of total revenue, while service revenue is only $9.7 million, highlighting the company's reliance on its core subscription model. The deceleration is a key concern, but the sequential improvement suggests that the slowdown may be stabilizing, and the company's AI initiatives could reaccelerate growth.
Quarterly Revenue
$185053000.0B
2025-12
Revenue YoY Growth
+9.8%
YoY Comparison
Gross Margin
89.9%
Latest Quarter
Free Cash Flow
$311547000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is DOCS Overvalued?
Given that Doximity is profitable, the PE ratio is the primary valuation metric. The trailing PE is 22.2x, while the forward PE is 13.0x, implying that the market expects significant earnings growth over the next year. This gap is substantial, suggesting that analysts anticipate a strong rebound in profitability, likely driven by AI-driven efficiency gains and margin expansion. The forward PE of 13x is attractive for a company with a 30% net margin and 89% gross margin, but it also reflects the market's skepticism about the sustainability of growth.
PE
22.2x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 27x~104x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
15.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are elevated due to the sharp deceleration in revenue growth, which fell from 23% YoY to 9.8% in the latest quarter. While the company maintains a strong balance sheet with minimal debt (debt-to-equity of 0.01) and a current ratio of 6.09, the reliance on subscription revenue (94.8% of total) creates concentration risk. If subscription growth continues to slow or churn increases, the company's high net margin of 30.4% could compress, and the forward PE of 13x would quickly look less attractive. Additionally, the company's free cash flow of $311.5 million TTM is healthy, but any significant investment in AI or expansion could pressure margins in the near term.